home / stock / rvnc / rvnc news


RVNC News and Press, Revance Therapeutics Inc. From 04/12/24

Stock Information

Company Name: Revance Therapeutics Inc.
Stock Symbol: RVNC
Market: NASDAQ
Website: revance.com

Menu

RVNC RVNC Quote RVNC Short RVNC News RVNC Articles RVNC Message Board
Get RVNC Alerts

News, Short Squeeze, Breakout and More Instantly...

RVNC - Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one abstract examining the influence of DAXXIFY’s formulation on clinical performance ...

RVNC - Survey finds GLP-1 users more inclined to get aesthetic procedures

2024-03-17 17:09:16 ET More on AbbVie, Evolus, etc. AbbVie Inc. (ABBV) Barclays 26th Annual Global Healthcare Conference (Transcript) AbbVie: Comeback Expected After Humira Patent Expiration AbbVie Stock: I Was So Wrong, But This Is Way Too Fast Evolus prices...

RVNC - Revance stock rises after CEO discloses share purchase

2024-03-11 06:37:47 ET Read the full article on Seeking Alpha For further details see: Revance stock rises after CEO discloses share purchase

RVNC - Revance Announces Pricing of $100.0 Million Public Offering of Common Stock

Revance Therapeutics, Inc. (Nasdaq: RVNC) (“Revance” or the “Company”) today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $6.25 per share. T...

RVNC - Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update

– Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately 28% and 80% YoY growth, respectively. – Q4 DAXXIFY volume up 22% over Q3 2023, with over two-thirds of Q4 revenue attributable to reor...

RVNC - Expected US Company Earnings on Wednesday, February 28th, 2024

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...

RVNC - Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024

Conference Call Scheduled for Wednesday, February 28, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of market. Revance will h...

RVNC - Investors growing more bullish on SMID cap biotech stocks

2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...

RVNC - Revance jumps as Daxxify reimbursement simplified with permanent J-code

2024-02-02 08:49:31 ET Read the full article on Seeking Alpha For further details see: Revance jumps as Daxxify reimbursement simplified with permanent J-code

RVNC - KOPN, RVNC and MINM are among pre market gainers

2024-02-02 08:32:47 ET CCSC Technology International Holdings  ( CCTG ) +39% . Minim  ( MINM ) +38% . TruGolf Holdings  ( TRUG ) +36% . Kopin  ( KOPN ) +21% . Meta Platforms  ( META ) +17% Q4 earnings call rele...

Previous 10 Next 10